New drug ASKB589 tested against advanced cancers

NCT ID NCT04632108

Ongoing Disease control Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for this trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASKB589 (an experimental drug given by injection)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors, especially gastric and pancreatic cancers.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 199 participants, so the drug may not prove effective or safe enough for wider use. Side effects could be serious, including life-threatening events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer gastric cancer gastroesophageal junction adenocarcinoma malignant pancreatic neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMOR

Contacts and locations

Locations

Beijing cancer hospital

Beijing, Beijing Municipality, 100089, China
Linyi cancer hospital

Linyi, Shandong, 276000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.